Loading...

C MM

C

AC IMMUNE SA

(ACIU)

2024 6-K

Management Changes

15 May '26

CEO Retirement Announced

12 May '26

Financial Update

30 Apr '26

Trial Progress Announcement

30 Apr '26

Collaboration Amended

7 Apr '26

Financial Filing Summary

13 Mar '26

Clinical Trial Start

24 Feb '26

Trial Enrollment Update

17 Feb '26

Positive Data Release

11 Dec '25

Filing Update

4 Nov '25

Strategic Workforce Reduction

4 Sep '25

AC Immune Filing

5 Aug '25

AGM Results Summary

20 Jun '25

Management Change

11 Jun '25

Management Changes

19 May '25

Filing Overview

30 Apr '25

6-K Filing Summary

13 Mar '25

Management Changes

18 Dec '24

Safety Data Update

10 Dec '24

Positive Clinical Data

14 Nov '24

6-K Filing Update

5 Nov '24

New CMO Appointment

19 Sep '24

Milestone Payment Received

17 Sep '24

FDA Fast Track Granted

28 Aug '24

Open Market Sales

6 Aug '24

Filing Report Summary

6 Aug '24

New Drug Announcement

31 Jul '24

Fast Track Approval

25 Jul '24

Annual Meeting Results

20 Jun '24

Shareholders Meeting

21 May '24

Filing Insights

13 May '24

License Agreement

13 May '24

Form 6-K Filing

14 Mar '24

Agreement Termination

22 Jan '24

Filing Update

3 Jan '24

External Links:

SEC

On January 22, 2024, AC Immune SA announced the termination of its Research Collaboration and License Agreements with Genentech, regaining global rights to the drugs crenezumab and semorinemab.

AI Assistant

AC IMMUNE SA

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.